Latest News
Greenwich LifeSciences secures UK approval to expand Phase III breast cancer trial
22 July 2026 - US biopharmaceutical company Greenwich LifeSciences, Inc. (NASDAQ: GLSI) said on Wednesday it has received regulatory clearance to extend its Phase III FLAMINGO-01 trial into the United Kingdom, enabling the addition of 5–10 UK s...
Arrowhead reports positive Phase 3 results for plozasiran in severe hypertriglyceridaemia
22 July 2026 - Pharmaceutical company Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) reported positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridaemia, with both trials meeting ...
Zoetis introduces Portela for feline osteoarthritis pain relief in Canada and EU
22 July 2026 - Animal health company Zoetis Inc (NYSE: ZTS) announced on Wednesday that it has launched Portela (relfovetmab) in Canada and European Union member states, introducing the first long-acting anti-nerve growth factor monoclonal antibody t...
Ipsen completes Memo Therapeutics acquisition to strengthen rare disease pipeline
22 July 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that it has completed the acquisition of Memo Therapeutics AG, adding late-stage asset potravitug to its rare disease pipeline.Potravitug is...
Elephas Biosciences partners with Invitrocue to promote elive platform in Singapore and Malaysia
22 July 2026 - Elephas Biosciences Corporation, developer of an innovative live tissue platform for immunotherapy response prediction, announced on Tuesday that it has entered into an international partnership with life sciences company Invitrocue Pt...